DRKS00010952招募中3 期
Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trialinvestigating the efficacy of N-Acetylcysteine (NAC) and Integrated Preventive PsychologicalIntervention (IPPI) in Subjects Clinically at High Risk for Psychosis - ESPRIT B1
Zentralinstitut für seelische Gesundheit/Central Institute of Mental Health (ZI)0 个研究点目标入组 200 人开始时间: 2016年8月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •1. Age 18 – 40 years;
- •2. Subjects with the ability to follow study instructions and likely to attend and complete all required visits;
- •3. Written informed consent of the subject;
- •4. Subjects are able to speak, write and understand the German language sufficiently well (at the investigators discretion) to complete all required study procedures;
- •Specific inclusion criterion:
- •5.Clinical High Risk Criteria : ESPRIT Ultra-high risk criteria (Attenuated Positive Symptoms and/or Brief Llimited Intermittend Psychotic Symptoms and/or a combination of familial risk or schizotypal disorder with a significant loss of functioning; severity assessed by the Structured Interview for Prodromal Syndromes, SIPS 5.0)
- •and/or The Basic Symptom Criterion 'Cognitive Disturbances, COGDIS' (2/9 cognitive-perceptive basic symptoms; assessed by the Schizophrenia
- •Proneness Instrument – Adult Version, SPI-A)
排除标准
- •1. Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure;
- •2. Simultaneously participation in another clinical trial involving administration
- •of an investigational medicinal product within 30 days prior to clinical trial beginning. The simultaneous participation in a noninterventional clinical trial is permitted in case the subject is nevertheless
- •able and willing to attend and complete all required visits and in case there are no other contraindications;
- •3. Subjects with a physical or psychiatric condition which at the investigator’s
- •discretion may put the subject at other clinically significant risks than those that are defined as outcome of this study (development of a
- •first psychotic episode, functional deterioration), may confound the trial
- •results, or may interfere with the subject’s per protocol participation in
- •this clinical trial;
- •4. Acute Suicidality;
- •5. Known substance abuse or dependence according to DSM-IV-TR;
- •6. Patients with hepatic or renal failure, or with known problems of galactose intolerance, clinically significant lactase deficiency or glucose-galactose malabsorption or histamine-intolerance;
- •7. Subjects with known asthma bronchiale;
- •8. Subjects with a history of gastrointestinal ulcer;
- •9. Intake of antitussives (cough-relieving agents);
- •10. Intake of nitroglycerin
- •11. Exclusion criteria regarding special restrictions for females: Current pregnancy or pregnancy planned within 9 months after start of medication or nursing women and
- •12. Females of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine
- •contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable
- •by the investigator in individual cases.
- •Indication specific exclusion criteria:
- •13. Having had a psychotic episode for > 1 week (according to SIPS 5.0);
- •14. Having symptoms relevant for inclusion potentially arising from a known general medical disorder;
- •15. Life time antipsychotic medication for more than 30 days (cumulative number of days) at or above minimum dosage of the '1st episode psychosis' range of DGPPN S3 Guidelines (Exception: maximum dosage for aripiprazole 5 mg/d) (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, 2006);
- •16. Any intake of antipsychotic medication (i.e., independent of duration of intake) within the past 3 months before psychopathological baseline assessments (including self-ratings and screening assessments) at or above minimum dosage of the '1st episode psychosis' range of
- •DGPPN S3 Guidelines (Exception: maximum dosage for aripiprazole 5 mg/d) (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und
- •Nervenheilkunde, 2006);
- •17. Any intake of mood stabilizers (lithium, valproate, carbamazepine, oxcabazepine,
- •lamotrigine) > 30 days (cumulative number of days) during the past three months or any intake during the month before psychopathological baseline assessments;
- •18. Intake of antidepressants during the past 30 days before psychopathological baseline assessments;
- •19. Intake of benzodiazepines for more than 2 consecutive days during the past 5 days before psychopathological baseline assessments;
- •20. Psychotherapeutic intervention during the past 30 days before psychopathological
- •baseline asse
研究者
相似试验
进行中（未招募）
1 期
Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in Subjects Clinically at High Risk for PsychosisEUCTR2014-003076-22-DECentral Institute of Mental Health Mannheim (ZI)130
已完成
不适用
Primary prevention of psychosis through interventions in the prodromal phaseISRCTN20328848Stavanger University Hospital (Norway)240
终止
3 期
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"Prodromal SchizophreniaNCT03149107University Hospital, Bonn48
已完成
4 期
Second generation intervention research in the pre-psychotic phase of illness in schizophrenia and related psychosesSchizophrenia and other psychotic disordersMental Health - SchizophreniaMental Health - Other mental health disordersACTRN12605000247673Janssen-Cilag Pharmaceuticals119
进行中（未招募）
1 期
Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.Persons at risk of being prodromally symptomatic of psychosis (PAR)EUCTR2007-001573-28-DEniversität zu Köln